Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
"Buscopan" (hyoscine-n-butylbromide,
HBB
) is a smooth muscle relaxant regularly used in radiological and endoscopic procedures. One unwanted effect is temporary impairment of visual accommodation. Near and distance vision were assessed in 100 patients undergoing barium meal and barium enema studies. Visual testing was performed prior to the examination and repeated immediately before leaving the radiology department. Completed data was obtained in 90 patients. Of these, 37 were given a conventional 20 mg intravenous dose of
HBB
, 37 were given
glucagon
and 16 received no drug. No patient showed any impairment of distance vision. Minor abnormalities of near vision were observed in five patients. All had been given
HBB
. They were aged 50 years or less and had been retested 12-21 min after administration of the drug. It is suggested that the degree of visual impairment observed is not sufficient to impair driving ability. Routine questioning concerning history of glaucoma is unlikely to be of value; more appropriate would be a warning to seek urgent medical advice if eye pain or visual loss is experienced.
...
PMID:The ocular effects of hyoscine-n-butylbromide ("Buscopan") in radiological practice. 187 58
The aim of this prospective study was to compare the intraindividual aperistaltic effect of 40 mg hyoscine N-butylbromide (
HBB
/Buscopan) with that of 1 mg
glucagon
on small bowel motility by using magnetic resonance imaging (MRI). Ten healthy volunteers underwent two separate 1.5-T MRI studies (
HBB
/
glucagon
) after a standardized oral preparation with an aqueous solution of Gd-DOTA and ispaghula (Metamucil). A 2D T1-w GRE sequence was acquired (TR 2.7 ms/TE 1.3 ms, temporal resolution 0.25 s) before and after intravenous (i.v.) drug administration and motility was followed over 1 h. On the resulting images the cross-sectional luminal diameters were assessed and plotted over time. Baseline motility frequency, onset of aperistalsis, duration of arrest, reappearance of motility and return to normal motility were analysed. Significant differences regarding reliability and duration of aperistalsis were observed. In the
HBB
group aperistalsis lasted a mean of 6.8 +/- 5.3 min compared with 18.3 +/- 7 min after
glucagon
(p < 0.0001). In 50% of cases
HBB
did not accomplish aperistalsis, whereas
glucagon
always succeeded (p = 0.05). There were no significant differences in terms of baseline and end frequencies for the onset of aperistalsis (22.2 +/- 37.5 s
HBB
/13.4 +/- 9.2 s
glucagon
, p = 0.1), nor for the return to normal motility. Arrest of small bowel motion is achieved more reliably and lasts significantly longer after i.v. administration of 1 mg
glucagon
compared with 40 mg
HBB
.
...
PMID:Aperistaltic effect of hyoscine N-butylbromide versus glucagon on the small bowel assessed by magnetic resonance imaging. 1919 Sep 16